Here's Why Myokardia Inc. Stock Shot Up Today

Shares of Myokardia Inc. (NASDAQ: MYOK), a clinical-stage biotech developing treatments for inherited heart problems, took flight this morning. Positive data for its lead candidate propelled the stock 82.8% higher as of 11:42 a.m. EDT during Monday's session.

This morning, Myokardia announced results from a mid-stage clinical trial testing mavacamten's ability to help patients' abnormally strong hearts relax a little. The study met its main goal, lowering peak left ventricular outflow tract gradient for a small group of obstructive hypertrophic cardiomyopathy patients, with flying colors.

Image source: Getty Images.

Source: Fool.com